Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Expeditors International of Wshngtn Inc (EXPD) vs Moderna, Inc. (MRNA) Price & Performance

Expeditors International of Wshngtn IncTrade
Moderna, Inc.Trade

Price performance (Past 24H)

Key statistics

Expeditors International of Wshngtn Inc vs Moderna, Inc. — how do they compare? Expeditors International of Wshngtn Inc trades at $177.4 (market cap $23.27B), while Moderna, Inc. trades at $60.62 (market cap $23.88B). The key difference: Expeditors International of Wshngtn Inc and Moderna, Inc. are close in size by market cap, and Expeditors International of Wshngtn Inc pays a 0.91% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.

EXPDMRNA
Market Cap
$23.27B$23.88B
Sector
IndustrialsHealth
52-Week High
$182.80$81.80
52-Week Low
$113.13$22.36
Enterprise Value
$22.80B$20.03B
Dividend Yield
0.91%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Expeditors International of Wshngtn Inc

EXPD trades at $178.71, up 0.08% on the day, with a bullish technical signal and strong recent earnings beats. The stock is near its pivot point of $179, with support at $177 and resistance at $181. Revenue grew to $11.07B in 2025, with net income of $810.33M and a robust ROE of 42.6%. Recent Q2 2026 EPS of $2.03 beat estimates by 20%, driven by airfreight and customs strength.

Outlook is mixed; strong profitability and earnings momentum support upside toward the $181.14 consensus target, but analyst sentiment is cautious with 63.6% Hold ratings. Risks include ocean freight contraction and unsustainable growth from tariff policies. The stock offers a dividend but faces macroeconomic and competitive pressures.

Moderna, Inc.

Moderna (MRNA) stock trades at $59.17, up 9.86% recently, with a bullish technical signal and strong institutional buying interest. The company's Q2 2026 earnings beat expectations, and the FDA approval of its mRNA flu vaccine, mFLUSIVA, for adults 50+ marks a key post-pandemic milestone. However, fundamentals show declining revenue from $18.9B in 2022 to $1.9B in 2025 and persistent net losses, with a negative net income margin of -142.58% in 2025.

The outlook hinges on pipeline execution; while new vaccine approvals and cost-cutting efforts offer growth potential, the stock faces risks from high valuation multiples and ongoing profitability challenges. Analyst consensus is cautious with a $54.33 price target below the current price, reflecting mixed sentiment amid transitional phase uncertainties.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Expeditors International of Wshngtn Inc

Expeditors International of Washington is a non-asset-based third-party logistics provider, mainly focused on international freight forwarding. It employs sophisticated IT systems and contracts with airlines and ocean carriers to move customers' freight across the globe. The firm operates more than 200 full-service office locations worldwide, in addition to numerous satellite locations. In 2021, Expeditors derived 38% of consolidated net revenue from airfreight, 27% from ocean freight, and 35% from customs brokerage and other services.

Read more on EXPD

About Moderna, Inc.

Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.

Read more on MRNA